文献速递前列腺癌

镓-68 PSMA PET/CT 用于前列腺癌初始分期前瞻性验证

Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
PubMed 文献 · J Urol · 2019-09-06

该研究前瞻性纳入103例新诊断且MSKCC淋巴结转移风险>10%的前列腺癌患者,在扩大盆腔淋巴结清扫术前行68Ga-PSMA PET/CT,以病理为参考评估淋巴结转移诊断效能。患者层面敏感度41.5%、特异度90.9%,12.6%患者因PET结果改变治疗。

要点

  • 68Ga-PSMA PET/CT 检出淋巴结转移特异度高(90.9%)、敏感度中等(41.5%)。
  • 12.6%患者基于PET/CT结果改变了治疗决策。
  • 适用于MSKCC淋巴结转移风险>10%的新诊断前列腺癌术前分期。

核心结论

  • 在新诊断且MSKCC淋巴结转移风险>10%的前列腺癌患者中,68Ga-PSMA PET/CT检出淋巴结转移具有高特异度和中等敏感度,并导致12.6%患者治疗改变。

研究设计与样本

  • 前瞻性研究,2017年10月至2018年10月纳入新诊断前列腺癌且骨扫描阴性、MSKCC淋巴结转移风险>10%的患者。
  • 共103例患者纳入分析,其中97例行扩大盆腔淋巴结清扫术。

主要发现

  • 41例患者(42.3%)共发现85枚淋巴结转移。
  • PET阳性17例,患者层面敏感度41.5%(95%CI 26.7-57.8),特异度90.9%(95%CI 79.3-96.6)。
  • 阳性预测值77.3%(95%CI 54.2-91.3),阴性预测值67.6%(95%CI 55.6-77.7)。
  • 13例患者(12.6%)因PET结果改变治疗。

关键数值与推荐

  • 以组织病理学为参考标准,按患者和切除模板计算敏感度、特异度、阳性预测值和阴性预测值。
  • 扫描结果在第二次肿瘤委员会会议上评估以判断是否改变管理。

临床怎么用

  • 对MSKCC淋巴结转移风险>10%的新诊断前列腺癌患者,可考虑术前行68Ga-PSMA PET/CT辅助分期。
  • PET阳性者特异度高,有助于支持治疗决策调整;但敏感度中等,阴性结果不能排除淋巴结转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prospective validation of 68Ga prostate specific membrane antigen positron emission tomography/computerized tomography is lacking in initial staging of prostate cancer. In this study we evaluated the diagnostic accuracy of 68Ga prostate specific membrane antigen positron emission tomography/computerized tomography for detecting lymph node metastasis in patients with intermediate-high risk prostate cancer. MATERIALS AND METHODS: Patients with newly diagnosed prostate cancer and negative bone scan findings at greater than 10% MSKCC (Memorial Sloan Kettering Cancer Center) risk for lymph node metastasis were prospectively included in study from October 2017 to October 2018. In candidates for extended pelvic lymph node dissection 68Ga prostate specific membrane antigen positron emission tomography/computerized tomography was performed prior to planned surgery. Scan results were evaluated in a second tumor board meeting to assess a potential change of management. Sensitivity, specificity, and positive and negative predictive value for detecting lymph node metastasis were calculated per patient and per resection template using histopathology as the reference. A positron emission tomography based change of management was also reported. RESULTS: A total of 103 patients were eligible for analysis and 97 extended pelvic lymph node dissections were performed. In 41 patients (42.3%) there was a total of 85 lymph node metastases. Positron emission tomography was positive in 17 patients, resulting in 41.5% patient based sensitivity (95% CI 26.7-57.8) for detecting lymph node metastasis. The patient based specificity rate was 90.9% (95% CI 79.3-96.6), and positive and negative predictive values were 77.3% (95% CI 54.2-91.3) and 67.6% (95% CI 55.6-77.7), respectively. A positron emission tomography based change of treatment was observed in 13 patients (12.6%). CONCLUSIONS: In patients with newly diagnosed prostate cancer at greater than 10% MSKCC risk for lymph node involvement 68Ga prostate specific membrane antigen positron emission tomography/computerized tomography detected lymph node metastasis with high specificity and moderate sensitivity. This led to a treatment change in 12.6% of patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. van Kalmthout LWM, van Melick HHE, Lavalaye J, et al. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. J Urol. 2019. PMID: 31487220. doi:10.1097/JU.0000000000000531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。